GOURI in Daegu: which skin types is it actually for
GOURI (liquid-form polycaprolactone) is widely described as suited to thin skin. This column sets out how far that has been measured, where inference begins, and — more usefully — the skin states in which it drops out of consideration.
The short answer
GOURI addresses dermal thinning and texture. Volume loss, descent and pigment are not its targets. So “is it right for my skin” is less a question about skin type than about which layer your dissatisfaction lives in. And “better for thin skin” is inferred from the formulation: no human study compares outcomes by skin thickness, because the published human data totals 33 subjects.
The axes we actually use
In aesthetic consultations “skin type” usually means dry, oily or combination. Choosing a booster uses different axes. We look at five.
- Dermal thickness — how it feels when pinched, texture, how light reflects
- Volume — how much fat there is and where it sits (atrophy versus migration)
- Descent — the difference between lying down and sitting up
- Pigment and vessels — brown or red
- Barrier status — how readily skin flushes, recent laser or acid procedures
GOURI touches the first of those five. So two people with “dry skin” may need completely different things: if the cause is a damaged barrier, repair comes before any injection; if it is volume loss, the formulation itself is wrong.
By skin state — candidate, or not
| Skin state | Verdict | Why |
|---|---|---|
| Thin, dry, coarsening texture | Candidate | A particle-free solution spreading thinly in the dermis fits the direction. But “thickness increases” has not been measured in humans |
| Thick, sebaceous skin | Candidate, conditionally | Nothing in the formulation excludes it; there is simply no comparative data for this skin |
| Volume loss is the main issue | Not a candidate | This is not a filling material |
| Descent is the main issue | Not a candidate | Wrong layer — devices, threads or surgery |
| Pigment (brown) or vessels (red) | Not a candidate | Adding dermal collagen is not the same as reversing colour |
| Impaired barrier, flushes easily | We hold | Injection is itself an insult. Restoring the barrier first also makes the result assessable |
| PCL, PLLA or CaHA already in that area | We hold | All irreversible. Establishing what went in, where and when comes first |
| Pregnancy or breastfeeding | Not a candidate | No data exists in this group |
Five rows read “not a candidate”. GOURI is the wrong answer more often than it is the right one — which is why a consultation that begins with a product name has to be run backwards before it can be useful.
How far “suited to thin skin” has been confirmed
| Item | What exists |
|---|---|
| Published human data | 30-patient pilot + 2-case report + 1-case report = 33 subjects |
| Longest follow-up | Six months |
| Human histology | We found none |
| Subgroup analysis by skin type | None — not possible at this sample size |
| Animal data | Rat photoaging model, 40 animals: dermal thickness (p < 0.001) and type I collagen (p = 0.003) significantly increased at six weeks |
The animal finding is established. Whether the same happens in human skin has never been confirmed histologically. “Suited to thin skin” sits on top of that gap. We do use the phrase — but we label it as inference when we do.
Watch for transferred numbers. Microsphere PCL (Ellansé) does have human histology — 13 subjects, +26.7% ± 9.3% at one year, and +48.1% ± 5.8% at four years in three subjects (P < 0.001). Those figures belong to a different formulation, and no study compares the two in humans. If they are offered as GOURI's evidence, check which formulation is meant.
If GOURI drops out, what is left
Listing the alternatives matters, as long as they are read as different targets rather than a ranking.
- Skin quality, but you want more data — Rejuran (polynucleotide) passed a Korean phase 3 trial (70 analysed, 95.7% vs 94.3% improvement). Note what that trial showed: non-inferiority to a hyaluronic acid product, not superiority to placebo.
- Immediate hydration is the goal — hyaluronic acid boosters. Worth knowing that cross-linked HA has also been reported to raise type I and III procollagen on human biopsy (11 subjects, P < .05); collagen stimulation is not the exclusive property of one class.
- Descent is the main issue — devices. Decide which layer is being targeted before choosing a brand.
- Volume loss — a filling material, and reviewing a reversible option first is the safer order.
The class-by-class data is tabulated in GOURI vs Rejuran vs Rituo vs Juvelook vs Sculptra.
How Miso Clinic decides whether to treat
- Layer before product. We give the proportions of skin quality, volume, descent and pigment, area by area.
- We label inference as inference. “Suited to thin skin” is inference; “33 subjects, six months” is measurement.
- We state irreversibility first. Hyaluronidase does not dissolve it.
- We postpone when the barrier is impaired. An injection is an insult too.
- Where a group or an area has no data, we say so — pregnancy and breastfeeding, and off-face areas.
The items to check before choosing a clinic are in seven things to check before you choose a clinic. The product itself is documented at GOURI reference page.
Summary
Established
- 33 subjects, six months maximum; no human histology
- Animal model: dermal thickness and type I collagen up at six weeks
- Not dissolved by hyaluronidase
Inferred
- A particle-free solution spreads thinly — that is as far as the inference goes
Not established
- Any difference in outcome by skin thickness or type
- Dose per area; any data in pregnancy or breastfeeding
- The Korean authorisation text (database queries blocked)
Frequently asked questions
Is GOURI only for thin skin?
Thin, dry skin is the best-fitting candidate by direction, but nothing excludes thicker skin. Since no human study compares outcomes across skin types, there is no basis either for calling it thin-skin-only or for claiming it performs identically for everyone.
My cheeks look hollow. Will GOURI fill them?
Liquid-form PCL is not a filling formulation, so if volume loss is the main issue it drops out. Whether hollowness is fat atrophy, descent or dermal thinning differs by area, so the proportions are worth establishing in consultation first.
My skin is sensitive and flushes often. Can I have it?
When the barrier is impaired we prefer to postpone. The injection is itself an insult, and flushing afterwards becomes hard to attribute. Restoring the barrier first also makes the result easier to judge.
Does suitability change with age?
Skin state matters more than age. That said, as descent and volume loss take up more of the picture, the share a booster alone can address shrinks. No GOURI data compares outcomes by age group.
I am pregnant or breastfeeding. Is it possible?
We do not recommend it, because no data exists in this group. No data means neither that harm has been shown nor that safety has been shown.
Rejuran or GOURI for my skin?
Their targets overlap but the data does not. Rejuran passed a Korean phase 3 with 70 subjects analysed; GOURI has 33 subjects. Note also that the phase 3 demonstrated non-inferiority to a hyaluronic acid product. Choose with the data, reversibility and target area on the table together.
I had a booster elsewhere. Can I add GOURI?
What went in, where and when comes first. If irreversible material - PCL, PLLA, CaHA - is in the same area, we advise holding, because layering makes any later problem impossible to attribute.
How long does one session last?
The longest measured follow-up is six months. The widely quoted six to twelve months describes how long the material takes to degrade, not how long an effect lasts. Beyond that window there is no human measurement.
Read next
Product page
The product itself is set out here. GOURI: liquid polycaprolactone as a collagen stimulator
Who wrote this
Written and reviewed by Lee Chi-Hak, MD, medical director of Miso Clinic in Daegu, South Korea. Every study cited above is given together with its design, its size and the limitations the authors themselves recorded, and where we could not find data, we have said that we could not find any.
| Medical director | Lee Chi-Hak, MD |
|---|---|
| Address | 4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, South Korea · Exit 1, Kyungpook National University Hospital Station |
| Phone | +82-53-428-2700 |
| Hours | Weekdays 11:00–19:00 (lunch 13:00–14:00) / Saturday 10:00–16:00 (no lunch break) / Closed Sundays and public holidays |
| Columns | All clinical columns |
| Reference library | All booster and device references |
References
- Ponzo M et al., PRS Global Open 2025;13(11), PMID 41210393 — 30-patient pilot, six months. With three further cases, total human data is 33 subjects; we found no human histology for this formulation.
- Rat photoaging model — 40 animals; dermal thickness (p < 0.001) and type I collagen (p = 0.003) up at six weeks.
- Microsphere PCL human histology — 13 subjects, +26.7% ± 9.3% at one year; +48.1% ± 5.8% at four years in three subjects (P < 0.001). No human study compares the two formulations.
- Rejuran (PN) Korean phase 3 — J Korean Med Sci 2014;29(Suppl 3):S201–S209. 72 enrolled / 70 analysed, 95.7% vs 94.3%, non-inferiority margin −15% met, comparator a hyaluronic acid product.
- Cross-linked hyaluronic acid and procollagen — human biopsy, 11 subjects, P < .05.
- GOURI manufacturer's official FAQ — face only; hand and neck data being collected; one session plus optional 1–2 at 4–6 weeks.
- The Korean marketing-authorisation text could not be retrieved (database queries blocked). We also found no data in pregnancy or breastfeeding.
Everything in this column is general information and does not replace medical diagnosis or treatment. Effects and side effects vary with individual skin condition, age and underlying illness, and the same result is not guaranteed for everyone. Any decision to proceed should be made in an in-person consultation with a physician.
← Clinical columns · Reference library · Miso Clinic home
한국어 · English